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Abstract: Fingolimod (FTY720) is the ﬁ  rst of a novel class: sphingosine 1-phosphate (S1P) receptor modulator and is cur-
rently in phase 3 clinical trials for multiple sclerosis (MS). FTY720 was ﬁ  rst synthesized in 1992 by chemical modiﬁ  cation 
of an immunosuppressive natural product, ISP-I (myriocin). ISP-I was isolated from the culture broth of Isaria sinclairii, 
a type of vegetative wasp that was an ‘eternal youth’ nostrum in traditional Chinese medicine. ISP-I is an amino acid having 
three successive asymmetric centers and some functionalities. We simpliﬁ  ed the structure drastically to ﬁ  nd a nonchiral 
symmetric 2-substitued-2-aminopropane-1,3-diol framework for an in vivo immunosuppressive activity (inhibition of rat 
skin allograft rejection test or prolonging effect on rat skin allograft survival) and ﬁ  nally discovered FTY720. During the 
course of the lead optimization process, we encountered an unexpected dramatic change of the mechanism of action with 
an in vivo output unchanged. Since it proved that FTY720 did not inhibit serine palmitoyltransferase that is the target enzyme 
of ISP-I, reverse pharmacological approaches have been preformed to elucidate that FTY720 is mainly phosphorylated by 
sphingosine kinease 2 in vivo and the phosphorylated drug acts as a potent agonist of four of the ﬁ  ve G protein coupled 
receptors for S1P: S1P1, S1P3, S1P4 and S1P5. Evidence has accumulated that immunomodulation by FTY720-P is based 
on agonism at the S1P1 receptor. Medicinal chemistry targeting S1P1 receptor agonists is currently in progress. The FTY720 
story provides a methodology where in vivo screens rather than in vitro screens play important roles in the lead optimization. 
Unlike recent drug discovery methodologies, such a strategy as adopted by the FTY720 program would more likely meet 
serendipity.
Keywords: FTY720, Fingolimod, sphingosine 1-phosphate, sphingosine 1-phosphate receptor agonist, immunomodulator, 
multiple sclerosis
Introduction
Immunosuppressants are clinically important for organ transplantations and the treatment of autoim-
mune diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus 
(SLE), and psoriasis. Calcineurin inhibitors cyclosporin A (CsA) and tacrolimus (FK506) are clinically 
used as an immunosuppressant (Fig. 1). (1, 2) Both CsA and FK506 inhibit the production of type 1 
helper T cell-derived cytokines such as interleukin 2 (IL-2) and interferon-gamma that induce cytotoxic 
T cells but induce renal dysfunction and other side effects at higher doses. (3, 4) CsA was isolated from 
a fungus, Tolypocladium inﬂ  atum. The historic discovery of the immunosuppressant from a fungus 
stimulated other researchers to search for immunosuppressants from various fungi. Fujita and coworkers 
also screened other fungi as a part of their screening program of fungal extracts and ﬁ  nally isolated an 
immunosuppressant, ISP-I that was 10- to 100-fold more potent than CsA from Isaria sinclairii, a kind 
of vegetative wasp that is an ‘‘eternal youth’’ nostrum in traditional Chinese herbal medicine (Fig. 1). 
(5) ISP-I was found to inhibit mouse allogeneic mixed lymphocyte reaction (MLR) in vitro and to be 
effective in rat skin allograft in vivo. (6, 7) The chemical structure of ISP-I since proved to be identical 
to those of myriocin and thermozymocidine, which had been isolated as an antifungal agent from 
Myriococcum albomyces (ATCC16425) and Mycelia sterilia (ATCC20349), respectively. (8, 9, 10)12
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ISP-I is structurally even simpler than CsA and 
FK506. While the molecular weight was rather 
diminished compared with CsA, ISP-I was toxic 
and had unfavorable physicochemical properties 
such as low solubility. Lead optimization of ISP-I 
was based on the simpliﬁ  cation of the structure. 
Eventually, the modiﬁ  cation led to a novel synthetic 
compound, 2-amino-2-[2-(4-octylphenyl)ethyl]
propane-1,3-diol hydrochloride (FTY720), which 
has more potent immunosuppressive activity and 
less toxicity than the lead ISP-I (Fig. 1). (11, 12)
MS is a progressive and debilitating disorder of 
the central nervous system that frequently affects 
young adults. MS is believed to be one of autoim-
mune diseases in which autoreactive T cells attack 
myelin sheaths, leading to demyelination and 
axonal damage. (13) Interferon beta and glatiramer 
acetate are currently approved as immunomodu-
lating treatments for MS. Both are administered 
either subcutaneously or intramuscularly. Inter-
ferons are associated with systemic reactions in 
more than 60% of patients, with implications for 
adherence to treatment. Orally available low 
molecular drugs with less toxicity have been 
longed for. In a proof-of-concept study (Phase 2 
clinical trial), FTY720 reduced the number of 
lesions detected on magnetic resonance imaging 
(MRI) and clinical disease activity in patients with 
relapsing multiple sclerosis. (13) In this study, 
FTY720 was well tolerated. While the treatment 
induced a transient reduction of heart rate that was 
maximal at six hours after the ﬁ  rst dosing, the heart 
rate returned to baseline with continuous treatment. 
It was shown that oral FTY720 may be a treatment 
option for MS. International Phase 3 clinical trials 
for further evaluation in large-scale, long-term 
clinical studies are currently under way.
Applications of FTY720 for other indications 
have been widely investigated. It has been reported 
that FTY720 would be a potent anticancer 
agent. (14–17) It has been reported that an inhibi-
tory effect of FTY720 on airway inﬂ  ammation has 
been reported, suggesting that it may be useful for 
allergic diseases such as asthma. (18) It has been 
suggested that FTY720 may be efﬁ  cacious in beta-
amyloid-related inﬂ  ammatory diseases such as 
Alzheimer’s disease. (19) A protective effect 
against immune liver injury models has also been 
reported. (20)
A Fortuitous Discovery of FTY720
Naturally occurring ISP-I showed a potent inhibi-
tory effect on mouse allogeneic mixed lymphocyte 
reaction (MLR) in vitro and prolonged rat skin 
graft survival time in vivo. (6) Optimization was 
conducted using both in vitro and in vitro assays 
as screens. The in vitro assay is based on the prin-
ciple that mouse MLR is caused by T cell prolif-
eration stimulated with alloanitigen when mouse 
lymphocytes from two different strains are 
co-cultured. We carried out the assay by culturing 
BALB/c mouse spleen cells as responder cells with 
mitomycin-pretreated C57BL/6 mouse spleen cells 
Figure 1. Structure of CsA, FK506, ISP-I and FTY720.
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as stimulator cells. It should be mentioned that the 
selection of this particular evaluation system as the 
in vitro screen became crucial in the latter half of 
the FTY720 story because it turned out some time 
after the discovery of FTY720 that different assay 
systems using mice other than the above-mentioned 
ones did not work in evaluating in vitro immuno-
suppressive activity of FTY720-related compounds. 
Test compounds were evaluated in skin allograft 
in major histocompatibility complex-compatible 
rat strain combination between LEW donor and 
F344 recipient in vivo. Importantly, all the 
compounds synthesized were basically evaluated 
using the whole animal model (rat skin allograft 
model). It should be emphasized that FTY720 
program was sustained mainly by the highly reli-
able in vivo screening system that required proﬁ  -
cient transplant operation skills and long evaluation 
periods (sometimes more than ﬁ  fty days).
Immunosuppressive ISP-I homologues, myces-
tericins were isolated from another fungus. (7, 21, 
22) The SAR studies on these ISP-I homologues, 
including semi-synthetic derivatives, revealed that 
neither the functionalities (the 14-ketone, the 6-
double bond, and the 4-hydroxy group) nor the 
conﬁ  guration at the carbon bearing the 3-hydroxy 
group are so important for its activity; however, 
critical problems such as toxicity and insolubility 
remained to be solved. Therefore, simpliﬁ  cation 
of the structure of ISP-I was conducted to reduce 
its toxicity and to improve its physicochemical 
properties (Fig. 2). The simpliﬁ  cation process 
consisted of removal of the side chain functionalities 
and elimination of chiral centers. During the course 
of the process, a compound (ISP-I-28) where the 
carboxylic acid of ISP-I was transformed to the 
hydroxymethyl group was found not only to 
prolong the rat skin survival time more effectively 
but also to be approximately 30-fold less toxic than 
ISP-I. (7) Since the conversion of the carboxylic 
acid to the hydroxymethyl group proved to be 
highly advantageous from toxicological (less 
toxic), pharmacological (more effective), synthetic 
(reduction of the number of asymmetric carbons), 
and physicochemical (better solubility) points of 
view, a thorough simpliﬁ  cation was conducted to 
ﬁ  nally lead to much more simpliﬁ  ed structure, 2-
alkyl-2-aminopropane-1,3-diol represented by an 
analog having an eighteen carbon alkyl chain, ISP-
I-36. The modiﬁ  cation of the side chain length led 
to ISP-I-55. The compound with a fourteen carbon 
alkyl chain was much more effective both in vitro 
and in vivo and much less toxic than ISP-I. (6, 7)
ISP-I-55 was further modiﬁ  ed by introducing a 
phenylene moiety in a proper position within the 
side chain in the expectation for a favorable confor-
mation restricting effect of the phenyl group and 
ﬁ  nally FTY720 was synthesized in 1992 (Fig. 2). (11) 
The position of the phenyl group is highly critical 
for its potent activity. The other analogs having the 
phenylene moiety in a different position displayed 
obviously diminished activity compared to FTY720 
(Fig. 2). FTY720 was more potent than ISP-I-55 
in vivo while it displayed comparable activity to 
ISP-I-55 in vitro. Furthermore FTY720, having a 
phenyl ring in it, was considered to be more 
Figure 2. Optimization of the structure starting from ISP-I.
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favorable in various tests in ADME and toxicology 
studies as well as in clinical trials because FTY720 
is easier to detect than ISP-I-55 having no aromatic 
rings. Starting from ISP-I, drastic simpliﬁ  cation of 
the structure was effective in improving in vitro 
and in vivo activity, toxicity, and physicochemical 
properties, leading to the discovery of FTY720 as 
an immunomodulator.
In 1995, the lead ISP-I was found to inhibit 
serine palmitoyltransferase (SPT) involved in 
sphingolipid biosynthesis. (23) It was surprising 
that neither FTY720 nor ISP-I-55 displayed the 
inhibitory activity against the enzyme.(12, 24) It 
is obvious that the mechanism of action changed 
sometime during the optimization process from 
ISP-I to FTY720. However, for some time after 
the discovery of FTY720, the change of the 
mechanism had not been realized. If the SPT inhi-
bition assay had been substituted for the MLR 
assay as the ﬁ  rst screen, FTY720 might not have 
been discovered. Fortunately, the target of ISP-I 
was not known at the time of the FTY720 screening. 
It was fortuitous that the in vitro cell-based evalu-
ating system (allogeneic MLR using the particular 
combination of BALB/c responder cells and 
C57BL/6 stimulator cells) worked even after the 
mechanism of action changed.
Where did the mechanism of action change? 
Although it remains to be examined, we speculate 
that it happened at ISP-1-28, ISP-I-36 or some-
where from ISP-1-28 to ISP-I-36. The next ques-
tion arose as to what is the real mechanism of 
action of FTY720. Another seven years were 
needed until the molecular basis of immunosup-
pressive activity of FTY720 was proposed in 
2002.
FTY720: Pharmacological 
Actions and Mechanisms of Action
FTY720 contains a prochiral quarternary carbon 
atom bearing two hydroxylmethyl groups (Fig. 3). 
Replacement of one of the hydroxylmethyl groups 
by an alkyl substituent such as methyl afforded an 
FTY720 analog as a mixture of racemates. Optical 
resolution of the racemate was performed and 
pharmacological evaluation of each enantiomer 
revealed that the pro-(S) hydroxymethyl group of 
FTY720 is much more important for biological 
activity than the other. (25) While the pro-(S) 
hydroxymethyl group is biologically critical, the 
biologically less important pro-(R) hydroxymethyl 
group may play important roles chemically and 
physicochemically in simplifying the molecule 
(deletion of the chiral center by symmetrization) 
and improving the solubility.
FTY720, at 0.1 mg/kg or higher doses, signif-
icantly prolongs skin or cardiac allograft survival 
and host survival in lethal graft versus host reac-
tion (GvHR) in rats (Table 1). (26–29) In addition, 
combination treatment with FTY720 and a 
subtherapeutic dose of cyclosporin A (CsA) or 
tacrolimus (FK506) results in a synergistic effect 
on canine renal allograft as well as rat skin or 
cardiac allografts. (26, 27, 29–35)
A striking feature of FTY720 is the induction 
of a marked decrease in the number of peripheral 
blood lymphocytes, especially T-cells, at doses that 
prolong allograft survival. (26, 27, 36) Since a 
whole animal study using this phenomenon was 
reported, (12, 25) assay systems where the decrease 
in the number of peripheral blood lymphocytes is 
counted as an index of immunosuppression has 
been widely used to evaluate the immunosuppres-
sive activity of test compounds. FTY720 does not 
impair lymphocyte function, including T-cell acti-
vation, but instead induces the sequestration of 
circulating mature lymphocytes into the secondary 
lymphoid tissues and decreases T-cell inﬁ  ltration 
into grafted organs and this is presumed to be the 
main mechanism of FTY720 immunosuppressive 
activity. (34–37, 38) Comparison of the effects of 
FTY720 in various models including transplanta-
tion models and autoimmune models with those of 
calcinuerin inhibitors has been reported. (29, 39)
As described above, FTY720, unlike ISP-I, does 
not inhibit serine palmitoyltransferase, (12, 24) the 
ﬁ  rst enzyme in sphingolipid biosynthesis, but both 
molecules are structurally similar to sphingosine. 
Sphingosine is mainly phosphorylated by sphingosine 
kinase 1 into S1P that is a multi-functional lysophos-
pholipid mediator and stimulates multiple signaling 
pathways. S1P binds with nanomolar (nM) afﬁ  nities 
to ﬁ  ve related G-protein-coupled receptors (GPCRs), 
termed S1P1-5 (formerly Edg-1, -5, -3, -6, and-8). 
FTY720 is effectively phosphorylated by sphingosine 
NH2 HO
HO
Pro-(S): biologically critical
Pro-(R): chemically and physicochemically important
Figure 3. Role of the hydroxymethyl groups of FTY720.15
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kinase 2 and FTY720-phosphate (FTY720-P) is a high 
afﬁ  nity agonist for sphingosine 1-phosphate (S1P) 
receptors (Fig. 4). (40, 41, 42)
Evidence has accumulated that S1P receptor type 
1 (S1P1) is essential for lymphocyte recirculation 
and that S1P1 regulates lymphocyte egress from 
thymus and secondary lymphoid tissues. (43, 44, 
45) In mice whose hematopoietic cells lack S1P1, 
no T-cells are found in the periphery because mature 
T-cells are unable to exit the thymus and secondary 
lymphoid tissues. (44) Moreover, S1P1-dependent 
chemotactic responsiveness is strongly up-regulated 
in T-cell development before exit from the thymus, 
whereas S1P1 is down-regulated during peripheral 
lymphocyte activation, and this is associated with 
retention in lymphoid tissues. (44, 46) It has been 
suggested that FTY720-P internalizes S1P1 on 
lymphocytes and inhibits S1P/S1P1-dependent 
lymphocyte egress from secondary lymphoid 
tissues and thymus (Fig. 5). (44, 45) FTY720 treat-
ment down-regulates S1P1, creating a temporary 
pharmacological S1P1-null state in lymphocytes, 
(44) providing an explanation for the mechanism 
of FTY720-induced lymphocyte sequestration; 
therefore, FTY720-P is termed a functional antag-
onist. (47) Moreover, it has been reported that S1P 
induces S1P1 internalization and recycling while 
FTY720-P induces S1P1 internalization and degra-
dation.(48) This is a decisive difference between 
S1P and FTY720-P.
Interestingly, it has been reported that an S1P1 
antagonist does not affect the number of constitu-
tive blood lymphocytes.(48) It has been proposed 
that FTY720 may inhibit lymphocyte egress from 
lymph node (LN) by two independent mechanisms. 
One involves a down-modulation of S1P1 on T 
Table 1. Pharmacological properties of FTY720 and calcineurin inhibitors (CsA and FK506).
Response suppressed  Species  FTY720  CsA  FK506 
Allograft rejection  Rat (skin)  0.1 mg/kg  3 mg/kg  0.3 mg/kg 
  Rat (heart)  0.1 mg/kg  3 mg/kg  0.3 mg/kg 
Combination withCsA  Rat (skin)  0.1 mg/kg   
  Rat (heart)  0.1 mg/kg   
  Dog (Kidney)  0.03 mg/kg   
  Monkey (Kidney)  0.1 mg/kg   
GvHR  Rat  0.1 mg/kg  3 mg/kg  1 mg/kg
DTH (MeHSA)  Mouse  0.03 mg/kg  3 mg/kg  0.03 mg/kg 
Antibody production (to SRBC)  Rat  0.1 mg/kg  3 mg/kg  0.03 mg/kg 
Adjuvant-induced arthritis  Rat  0.1 mg/kg  3 mg/kg  1 mg/kg
Collagen-induce arthritis  Rat  0.1 mg/kg  3 mg/kg  1 mg/kg
EAE  Rat  0.1 mg/kg  10 mg/kg  1 mg/kg
Lupus nephritis (MRL/lpr)  Rat  0.1 mg/kg  10 mg/kg  1 mg/kg
Lymphopenia Mouse  0.1  mg/kg   
 Mouse  0.1  mg/kg   
 Rat  0.1  mg/kg   
 Dog  0.03  mg/kg   
 Monkey  0.1  mg/kg   
FTY720: Fingolimod; CsA: cyclosporin A; FK506:tacrolimus; GvHR, graft versus host reaction; DTH: delayed-type hyper sensitivity;MeHA
S,methylated human serum albmin; SRBC, sheep red blood cells; EAE, experimental autoimmune encephalomyelitis.
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cells and a reduced response of cells to the egress 
signal S1P. The other involves a persistent signaling 
at S1P1 on the sinus lining endothelium in the LN 
to increase barrier function and reduce transmigra-
tion of lymphocytes. (43, 49, 50) Thus, FTY720 
may differentially regulate S1P1 surface expression 
in T cells (functional antagonist) and endothelium 
(agonism). This may be the reason the S1P1 
receptor antagonist cannot reproduce the action of 
FTY720. Reverse pharmacology and medicinal 
chemistry have succeeded in providing an insight 
into the mechanism of action of FTY720 and have 
opened an avenue to the development of new S1P 
receptor agonists.
In terms of the immunosuppressive mechanism 
of FTY720, several mechanisms other than S1P1 
receptor agonism of FTY720-P have been 
proposed. One of those is related to immunosup-
pressive effects of FTY720-P through the S1P4 
receptor.
51 Direct effects of FTY720 itself (not 
FTY720-P) have also been reported. FTY720 has 
been reported to inhibit sphingosine lyase (SPL) 
that is responsible for the degradation of S1P. (52) 
It has been strongly suggested that SPL is a next 
promising target for the development of immu-
nomodulators because its inhibition can produce 
the decease of the number of peripheral lympho-
cytes like FTY720 treatment. (50, 53) More 
recently FTY720 has been demonstrated to inhibit 
cytosolic phospholipase A2 independently of S1P 
receptors. (54)
Exploration of Synthetic Methods 
for FTY720 and FTY720-P
Since the first synthetic route for FTY720 was 
reported, (11, 29) alternative methods have emerged. 
A shorter synthesis with Friedel-Crafts acylation of 
octylbenzene as a key step has been reported. (55) A 
regioselective ring opening of an epoxide with a 
system of MgSO4/MeOH/NaNO2 has been applied 
to synthesis of FTY720. (56) An iron-catalyzed cross-
coupling reaction has been used for a practical and 
scaleable synthesis of the intermediate, octylbenzene. 
(57) A synthetic route using the Petasis reaction as 
the key step has been reported. (58) A highly efﬁ  cient 
and practical synthesis using Sonogashira coupling 
reaction as a key step has been reported. (59)
 The 
synthetic route gave FTY720 in seven steps and high 
overall yield (64%) from a commercially available 
inexpensive material (Fig. 6).
FTY720 is a prochiral symmetric molecule 
having two hydroxymethyl groups at the quarternary 
carbon; therefore, purely chemical mono-phos-
phorylation gives a racemic mixture of (S)- and 
(R)-FTY720-P. Several methods for racemic and 
enantiomerically pure FTY720 phosphate (FTY720-
P) have been developed. An efﬁ  cient direct mono-
Figure 5. (S)-FTY720-P inhibits S1P/S1P1-dependent lymphocyte egress from lymphoid tissues by long-term internalization and degradation 
of S1P1.
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phosphorylation method using silver(I) oxide, 
tetrabenzyl pyrophosphate (TBPP), and tetrahex-
ylammonium iodide for racemic FTY720-P has 
been reported.(60) A properly protected racemic 
intermediate for FTY720-P were separated using a 
chiral HPLC column and the absolute conﬁ  gura-
tions of both enantiomers were determined by 
synthesizing the optically active intermediate 
starting from an L-serine-derived oxazolizine.(61) 
A practical asymmetric synthesis of (S)- and (R)-
FTY720-P using lipases and the determination of 
absolute conﬁ  gurations of FTY720-P have been 
reported. Only (S)-enantiomer was found to be 
biologically active (Fig. 7).(62)
The absolute conﬁ  guration of FTY720-P has 
been determined based on the crystal structure of 
a protected intermediate and it has been 
demonstrated that in vitro phosphorylation of 
FTY720 in rats and humans results exclusively in 
the biologically active (S)-enantiomer. (63) A 
Figure 6. Synthetic routes for FTY720.
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method for the preparation of both enantiomers of 
FTY720-P from 4-bromobenzaldehyde using the 
asymmetric Sharpless epoxidation as a key step 
has also been reported (Fig. 7). (64)
Development of S1P Agonists 
Based on Reverse Pharmacology
S1P is known to regulate heart rate, coronary 
artery blood ﬂ  ow, blood pressure and endothelial 
integrity. Most recently S1P has been shown to 
regulate the recirculation of lymphocytes through 
its high afﬁ  nity G-protein coupled receptors. 
FTY720 is mainly phosphorylated in vivo by 
sphingosine kinase 2 to mono phosphate (FTY720-
P), which is an agonist of S1P1, 3, 4, 5 receptors but 
not S1P2. (40, 41) While FTY720 was well toler-
ated in clinical studies, it has been reported to 
produce a transient reduction of heart rate. 
Researchers have been prompted to elucidate the 
contribution of individual receptors and solve 
questions as to which receptor(s) is responsible 
for immunosuppressive activity of FTY720-P and 
which receptor(s) causes adverse effects including 
the transient bradycardia. While S1P2- or S1P3-
kockout mice were successfully obtained, S1P1 
deletion resulted in the embryonic lethality. (65) 
Medicinal chemistry not only has helped reverse 
pharmacology by providing various molecular 
tools including selective agonists and/or antago-
nists to unveil the individual functions of S1P 
receptors but also has been targeting the creation 
of new S1P receptor agonists as immunosuppres-
sants with fewer adverse effects.
FTY720 and FTY720-P are in equilibrium 
with each other in vivo. In order to directly inves-
tigate the pharmacological effects of the agonism 
of S1P receptors, a nonhydrolyzable analogue of 
FTY720-P was synthesized as a phosphonate 
1(Fig. 8), which proved successful in eliciting 
the lymphopenic response although higher doses 
were required because of lower afﬁ  nity for S1P 
receptors as compared to FTY720-P. (66) There 
are two strategies for exploring S1P receptor 
agonists as immunosuppressants: one targets 
prodrugs like FTY720, and the other targets drugs 
with direct agonism at S1P receptors like 
FTY720-P and 1. Researchers in the Merck group 
have been making efforts based on the latter 
strategy. Their medicinal chemistry studies were 
initiated to obtain analogs with enhanced potency 
in vitro and in vivo starting from 1.
A phosphonate analog 2 obtained by the trans-
position of the 4-alkylphenylethyl group of 1 from 
the carbon onto the amino group and the deletion 
of the hydroxymethyl group maintains the nonse-
lective agonism for S1P receptors although the 
activity decreased (Fig. 8). (67) A further modiﬁ  ca-
tion gave a ﬁ  rst selective compound 3 that selects 
against the S1P3 subtype and shows an attenuated 
potential to cause the acute bradycardia.(68) This 
is consistent with the fact that the bradycardia 
induced by S1P receptor nonselective agonists in 
wild type mice is abolished in S1P3-/- mice. (65, 
69) It was found that no T cells were present in the 
periphery in lymphocyte cell-specific S1P1 
knockout mice. The phenomenon is similar to that 
observed in FTY720 treated wild-type mice. It was 
also found that FTY720 treatment down-regulated 
S1P1 to create a temporary pharmacological S1P1-
null state in lymphocytes. These ﬁ  ndings strongly 
suggest that S1P1 is crucial for controlling the 
lymphocyte trafﬁ  cking and that the immunosup-
pressive activity of FTY720 is based on agonism-
driven antagonism at the S1P1 receptor. (44) A high 
throughput screening of Gi-coupled S1P1 receptor 
agonists was conducted over the Merck sample 
collection, leading to the successful identiﬁ  cation 
of agonists represented by compound 4 having a 
totally different structure compared to those of 
sphingosine like agonists synthesized in the earlier 
stage. 4 was found to be a moderately potent but 
highly selective S1P1 receptor agonist.(70) This 
orally active S1P1 selective agonist has been widely 
used to elucidate the function of the S1P1 receptor 
and it has been reported that 4 indeed does not 
induce bradycardia. (65) Here, the goal of medic-
inal chemistry has been made clear. Compounds 
having S1P1 receptor agonism without S1P3 
receptor agonism are considered to be desirable 
S1P receptor immunomodulators with fewer 
adverse effects such as bradycardia.
Incorporation of the phenyl thiophene moiety of 4 
into azetizine carboxylate 5 which had been synthe-
sized as a conformationally constrained analog based 
on 2 and proved to be a ﬁ  rst orally active compound 
in this series and some modiﬁ  cation gave 6 (Fig. 8). 
6 and its analogs were found to be about 500- to 1000-
fold more selective for S1P1 over S1P3. (70) Optimi-
zation focused especially on PK proﬁ  les such as short 
half-life has been continuously performed on these 
classes of compounds.(71–76) During the course of 
the optimization, highly selective and potent S1P1 
receptor agonists such as 7 were discovered. (75) 7 19
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shows greater than 600-fold selectivity for the S1P1 
receptor over the other receptors (S1P2, 3, 4, 5) and oral 
administration of 7 to mice drives the lymphocyte-
lowering response, which again proved that selective 
agonism for the S1P1 receptor is sufﬁ  cient for lowering 
the number of peripheral lymphocytes.
Other groups also have made synthetic efforts to 
provide pharmacological tools to understand the 
individual S1P receptors. Researchers of University 
of Virginia have been investigating S1P receptor 
agonists as well as S1P receptor antagonists. (77–82) 
So far, they have synthesized several compounds 
exempliﬁ  ed by compound 8 as a modestly selective 
agonist at the S1P1 receptor (79) and compound 9 
as an antagonist at the S1P1 and S1P3 receptors 
(Fig. 9).(82) Interestingly, no signiﬁ  cant change in 
circulating lymphocyte numbers was observed at 
any dose of the S1P1 antagonist 9,(79) providing 
another proof that antagonism at the S1P1 receptor 
is insufﬁ  cient for mimicking the immunosuppres-
sive action of FTY720.
A pharmacophore based drug design for S1P3 
receptor antagonists has been reported. (83, 84) An 
aminocarboxylate analog 10, a low nanomolar, 
monoselective agonist of the S1P1 receptor has been 
reported to be effective in an animal model of trans-
plantation (Fig. 9). (85) Selective agonists for the 
S1P4 and S1P5 receptors have been developed.(86) 
These selective agents are expected to be molecular 
tools to explore the pharmacological roles of the 
S1P receptors. Recently a prodrug type (FTY720 
type) S1P receptor agonist, KRP-203 (11) has been 
reported. (87, 88) KRP-203 is structurally similar 
to FTY720 but has a lower potential to induce heart 
rate reduction in guinea pigs probably because KRP-
203 phosphate selectively activates the S1P1 
receptor but not the S1P3 receptor. It should be 
emphasized that the appearance of 11 indicates that 
the exploration of FTY720 analogs keeping its basic 
2-amonopropane-1,3-diol skeleton could lead to 
selective agonists for the S1P1 receptor. Exploration 
of second-generation S1P receptor agonists will 
continue on the basis of both strategies.
It would be very natural that a question is 
raised as to why FTY720 is effective in CNS 
diseases such as MS while the discussions on 
its mechanism have been focused mainly on the 
peripheral events such as the peripheral lympho-
cyte number decreasing. A key to solve this 
problem has been provided, suggesting that 
FTY720 easily crosses the blood-brain barrier 
(BBB) and its therapeutic effects on MS may 
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be displayed partly through the S1P5 receptor 
in the CNS. (50) Medicinal chemistry will contribute 
toward answering the issue by providing such 
chemical tools that resemble FTY720 but do not 
cross the BBB. Such chemical tools would also 
be useful for examining whether or not highly 
selective agonists for the S1P1 receptor are as 
effective in MS in humans as FTY720 one of 
whose metabolite, FTY720-P is a relatively 
non-selective S1P receptor agonist.
Conclusion
In summary, FTY720, after enantiospeciﬁ  c mono-
phosphorylation, acts as an agonist at the S1P1 
receptor, down-regulates and degrades the S1P1 
receptor on lymphocytes, and inhibits lymphocyte 
egress from secondary lymphoid tissues and 
thymus. FTY720 causes the sequestration of circu-
lating mature lymphocytes into lymphoid tissues 
and modulates the recirculation of lymphocytes 
between blood and lymphoid tissues. Conse-
quently, it is presumed that FTY720 decreases the 
trafﬁ  cking and the inﬁ  ltration of antigen-speciﬁ  c 
T-cells into grafted organs or inﬂ  ammatory sites 
in autoimmune diseases, thereby exerting powerful 
immunosuppressive activity. Since FTY720 
possesses a completely new mechanism of action, 
FTY720 should be a useful tool for the prevention 
of transplant rejection and a new therapeutic 
approach for autoimmune diseases, including MS, 
RA, and SLE.
About ﬁ  fteen years have passed since FTY720 
was ﬁ  rst synthesized in 1992. FTY720 showed 
excellent in vivo immunosuppressive activities in 
skin and cardiac allograft models and various 
autoimmune disease models (89) although the 
molecular mechanism underlying the pharmaco-
logical effects was not identiﬁ  ed. That stimulated 
reverse pharmacology to explore FTY720’s 
molecular mechanism. Since it was elucidated that 
FTY720’s target is the S1P receptors in 2002, very 
rapid explorations for understandings of S1P recep-
tors and their signaling have been developed. It 
has also been elucidated that S1P induces S1P1 
internalization and recycling while FTY720-P 
induces S1P1 internalization and degradation, 
which is a decisive difference between S1P and 
FTY720-P. Moreover, the development of second 
generations of FTY720 follow-up agents has been 
accelerated. FTY720 has been making enormous 
impacts on various research ﬁ  elds.
In this review we described the serendipitous 
discovery of FTY720 starting from a naturally 
occurring immunosuppressive agent ISP-I. In our 
FTY720 program, the drug discovery stage was 
driven mainly by a whole animal assay using a rat 
skin allograft model in vivo. It was fortunate for 
us that the mechanism of the lead ISP-I was eluci-
dated after the discovery of FTY720. Although we 
were unaware of the change of mechanism from 
SPT inhibition to S1P receptor agonism, the in vitro 
cell-based assay continued to work. The FTY720 
story reminds us that old-fashioned strategies using 
whole animal assays as the major screens are still 
highly useful for the discovery of drugs with totally 
new mechanisms of action.
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